



Financial Tear Sheet

Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Primary IR Contact

Michael Booth, D.Phil.
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: mbooth@incyte.com

Stock Performance

INCY (Common)

Exchange	NASDAQ (US Dollar)
Price	\$105.47
Change (%)	▼ 1.01 (0.95%)
Volume	1,034,805
52 Week Low	\$98.49
Market Cap	\$22,258,104,980
Rolling EPS	-0.76
PE Ratio	N/A
Shares Outstanding	211,037,309

Data as of November 17, 2017 4:00 p.m. ET



Recent Headlines

November 15, 2017

[Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib \(Jakafi®\) for the Treatment of Essential Thrombocythemia](#)

November 05, 2017

[ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo](#)

November 01, 2017

[More Than 30 Abstracts Highlighting Data from Incyte's Portfolio Accepted for Presentation at the 59th Annual ASH Meeting](#)

Events

There are currently no events scheduled.

Data provided by Nasdaq. Minimum 15 minutes delayed.